We evaluated the 75-g oral glucose tolerance test (OGTT)-induced modifications in glucose, insulin, and norepinephrine plasma concentrations, and in plasma, erythrocyte, and platelet magnesium levels in two groups of obese subjects (normotensive obese, NT-Ob, N = 19; hypertensive obese, HT- Ob, N = 15), and in a group of healthy control subjects (N = 12). During OGTT we detected a reduction in plasma magnesium concentrations and an increase in erythrocyte and platelet magnesium levels in the controls, whereas in both normotensive and hypertensive obese subjects, there was a reduction in plasma, erythrocyte, and platelet magnesium levels. Furthermore, no statistically significant difference was detected among the groups studied as regards Δ-plasma magnesium. On the other hand, Δ-erythrocyte magnesium and Δ-platelet magnesium were negative in the NT-Ob (Δ-erythrocyte magnesium: - 0.24 ± 0.08 mmol/L; Δ-platelet magnesium: -0.49 ± 0.09 μmol/108 cells) and HT-Ob (Δ-erythrocyte magnesium: -0.20 ± 0.10 mmol/L; Δ-platelet magnesium: -0.50 ± 0.11 μmol/108 cells) groups, and positive in control subjects (Δ-erythrocyte magnesium: 0.40 ± 0.08 μmol/L; Δ-platelet magnesium: 0.47 ± 0.09 mmol/108 cells). Finally, a direct correlation was found between Δ-norepinephrine and Δ-erythrocyte magnesium (r = 0.80, P <.01) in the control group, and a negative correlation was detected between Δ-norepinephrine and Δ-platelet magnesium (r = -0.58, P <.05) in the HT- Ob group. Our results seem to indicate that the insulin resistance status, the hyperglycemia, and the disregulation of the adrenergic system in obese subjects could be involved in the pathogenesis of the magnesium homeostasis impairment observed in the obese subjects.
- Oral glucose tolerance test
- Platelet magnesium
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine